Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01358058 · ClinicalTrials.gov registry record · NA
Proton Radiation Therapy for Gliomas
A NA study of Low Grade Glioma and WHO Grade 3 Glioma With IDH1 Mutation, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- NA
- Development phase
- 63
- Enrollment target
- 1
- Study location
NCT01358058: Active NA study of Low Grade Glioma and WHO Grade 3 Glioma With IDH1 Mutation, sponsored by Massachusetts General Hospital.
NCT01358058 is a NA study of Low Grade Glioma and WHO Grade 3 Glioma With IDH1 Mutation that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 63 participants, below the 111-participant average among 23 other Low Grade Glioma trials with a reported enrollment target (43% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01358058, a NA study of Low Grade Glioma and WHO Grade 3 Glioma With IDH1 Mutation, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 63 participants
- Enrollment target
- 1
- Study location
Study Summary
In this research study the investigators are looking at a type of radiation called proton radiation. Proton radiation has been shown to deliver virtually no radiation beyond the area of the tumor, sparing surrounding normal tissue from exposure. This may reduce side effects that patients would normally experience with conventional radiation therapy. In this research study the investigators are looking to determine if proton radiation with a reduced field size will be as effective in controlling tumor growth as photon therapy, while reducing the treatment-related side effects observed in patients with brain tumors.
Primary Outcome
To assess progression free survival of this treatment program.
Conditions Studied
Interventions
- RADIATION Proton radiation
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2011-05 |
| Est. Completion | 2027-11 |
| Phase | NA |
What the registry record for NCT01358058 still lists
NCT01358058 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 111-participant average among 23 other Low Grade Glioma trials with a reported enrollment target (43% lower).
The record links to 3 conditions, with Low Grade Glioma appearing as the primary indexed condition, and to 1 intervention - of which Proton radiation is the first listed.
NCT01358058 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01358058 about?
NCT01358058 is a clinical study titled "Proton Radiation Therapy for Gliomas". In this research study the investigators are looking at a type of radiation called proton radiation. Proton radiation has been shown to deliver virtually no radiation beyond the area of the tumor, sparing surrounding normal tissue from exposure. This may reduce side effects that patients would norma...
What is the current status of trial NCT01358058?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 63 participants. The study started on 2011-05. Estimated completion is 2027-11.
What conditions does trial NCT01358058 study?
This clinical trial studies the following conditions: Low Grade Glioma, WHO Grade 3 Glioma With IDH1 Mutation, WHO Grade 3 Glioma With 1p/19q Codeletion.
What interventions are being tested in trial NCT01358058?
The interventions under investigation include: Proton radiation (RADIATION).
Who is sponsoring clinical trial NCT01358058?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01358058 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Low Grade Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01358058's enrollment target sits among peer trials
63 17th of 23 higher than 7 of 23 other Low Grade Glioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Low Grade Glioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
HOBSCOTCH-CA (HOme-Based Self-management and COgnitive Training CHanges Lives in Brain CAncer)
RECRUITING · NA
-
Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas
RECRUITING · NA
-
Mind-Body Intervention in Glioma Couples
ACTIVE NOT RECRUITING · NA
-
A Vaccine Trial for Low Grade Gliomas
RECRUITING · Phase 2
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia